American Society of Addiction Medicine
American Society of Addiction Medicine
Lead: Impact of jail-based methadone or buprenorphine treatment on non-fatal opioid overdose after incarceration
Lead: Impact of jail-based methadone or buprenorphine treatment on non-fatal opioid overdose after incarceration
Lead: Impact of jail-based methadone or buprenorphine treatment on non-fatal opioid overdose after incarceration
Tuesday 9th April 2024
Explore the impact of jail-based methadone or buprenorphine treatment on non-fatal opioid overdoses after incarceration in this insightful episode.
7 minutes
Informative
Educational
Supportive
Engaging
Hopeful
About this podcast
Author:
American Society of Addiction Medicine
Overview:
Categories:
Innovative Treatments & Recovery Paths
Navigating Alcohol Dependency
Family Recovery from Addiction
Nutritional Pathways to Recovery
Navigating Intimate Relationships
Links:
Visit site
Episodes:
140 (View all)
Do you want to link to this podcast?
Get the buttons here!Impact of Jail-Based MOUD on Post-Incarceration Opioid Overdose
Episode Overview
- MOUD significantly reduces non-fatal overdoses in the first 14 days post-release.
- Continuity of care is crucial for sustained benefits post-incarceration.
- Adolescent nicotine exposure has long-term, sex-specific effects on behaviour and brain function.
- Low-dose ondansetron shows promise as a safe treatment for alcohol use disorder.
- Extended-release buprenorphine has high retention rates among older patients.
Those receiving MOUD had a significant reduction in non-fatal overdoses during the 14 days after release
This episode of 'This Week in Addiction Medicine from ASAM' dives into the impact of jail-based methadone or buprenorphine treatment on non-fatal opioid overdoses after incarceration. The hosts analyse a study that followed patients with opioid use disorder (OUD) incarcerated in New York City jails between 2011 and 2017. The research found that those who received medication for opioid use disorder (MOUD) just before release had a significant reduction in non-fatal overdoses during the first 14 days post-release.
However, the benefits did not extend beyond this period, possibly due to a lack of transition to outpatient treatment. This raises important questions about continuity of care and the need for better post-release support systems. The episode also explores various other studies, including one on adolescent nicotine exposure and its long-term effects on mood and anxiety, another on the safety of low-dose ondansetron for alcohol use disorder, and a study on the retention rates of extended-release buprenorphine treatment.
Each segment provides valuable insights into different aspects of addiction medicine, making it a must-listen for anyone interested in the latest research and developments in this field. Claire Rasmussen hosts the episode, offering a balanced mix of data analysis and real-world implications. The discussions are both informative and engaging, with a focus on practical takeaways for healthcare providers and policymakers.
Whether you're a medical professional or someone affected by addiction, this episode offers a wealth of knowledge and a deeper understanding of the complexities surrounding addiction treatment. Why should you tune in? This episode not only sheds light on critical issues but also provides actionable insights that could influence future policies and treatment approaches. It's an essential listen for staying updated on the latest advancements in addiction medicine.